Magnesium sulfate is used as a tocolytic, but clinical efficacy has been seriously questioned.
Introduction
The high incidence of preterm birth, >10% of births worldwide, remains unchanged despite much research effort and advancement in understanding uterine physiology 1 . It is the single largest cause of mortality and morbidity in newborns. Several tocolytics including oxytocinreceptor antagonists e.g. atosiban, prostaglandin synthesis inhibitors e.g. indomethacin, calcium channel blockers e.g. nifedipine, beta-2 agonists e.g. ritodrine, and magnesium sulfate (MgSO 4 ) have been developed to help prolong pregnancy, by reducing or slowing uterine contractions when preterm labour threatens. Unfortunately, it remains the case that none are ideal in terms of either efficacy or side effects, and perhaps not surprisingly there is little international consensus on which tocolytic to use to help manage spontaneous preterm labour.
Magnesium sulfate was described as a tocolytic in 1959 2 and shortly after became the preferred drug in treating preterm labour. More recently however, studies including Cochrane systemic reviews 3 4 have suggested that MgSO 4 is ineffective in the treatment of preterm labour. For example Crowther et al., (2014) concluded that it was no better than placebo for the primary outcome of giving birth within 48 hours of trial entry, and nor was there any significant difference for the primary outcome of serious infant morbidity 3 . In contrast, MgSO 4 has been shown to be the drug of choice in treatment of seizures in eclampsia 5 and prevention of preeclampsia in hypertensive pregnant women 6 . Additionally, MgSO 4 has been shown to have neuroprotective effects in preterm fetuses at delivery, reducing the risk of death, cerebral palsy, and gross motor dysfunction 7 . In contrast to clinical findings, in vitro studies have consistently found that Magnesium has a relaxant effect on smooth muscles including airway 8 and vascular 9 . Studies in myometrial smooth muscle show it to be a relaxant in several species [10] [11] [12] [13] ; it significantly inhibits contractions in a concentration-dependent manner 12, 14 .
In smooth muscles, Magnesium inhibits contractility via multiple mechanisms including effects on extracellular calcium entry, intracellular calcium release and calcium oscillations 15 . It primarily acts by competing with Ca 2+ at the L-type, voltage-operated Calcium channel (VOCC), resulting in a decrease in intracellular calcium concentration 15 The channel is comprised of four subunits, of which α-1 is the pore forming, voltage sensitive and conducting component, and the others modulate its activity. Progression of gestation has been linked to an increase in α-1 expression, and VOCC activity increases close to term [16] [17] [18] .
These findings suggest that Calcium channel density and expression increases with gestation.
As Magnesium's main action is at the Calcium channel, the question arises: could these changes in Calcium channel density and expression alter the effectiveness of Magnesium at different gestational ages?
Of the hormonal changes around labour, oxytocin has a pivotal role 19 . Oxytocin stimulates myometrial activity via a variety of mechanisms, including increasing Ca 2+ entry into the myometrium via L-type channels and stimulating Calcium release from the sarcoplasmic reticulum (SR) 20, 21 . Oxytocin stimulation would therefore be expected to mitigate the actions of Magnesium. Thus if women with threatened preterm labour had differing levels of oxytocin or differences in levels of expression of its receptor 22 , this may also alter responsiveness to Magnesium tocolysis in vivo. It would be of benefit if the in vivo and in vitro findings concerning Magnesium's effects on uterine contractility could be reconciled. This could then enable a stratification of which threatened spontaneous preterm labors may benefit from its use as a tocolytic. Our approach was to consider if there may be physiological factors which affect Magnesium's efficacy in vivo. Preterm births are defined as those before 37 completed weeks of gestation, and thus cover a very large gestational age range and much change in myometrial physiology and hormonal conditions [23] [24] [25] [26] . These changes can be anticipated to also affect Magnesium's tocolytic ability.
While the effect of Magnesium in animal and human term-pregnant myometrium on spontaneous [12] [13] [14] and oxytocin induced contractions 12, 14, 15 , has received some attention, the effect of Magnesium at different gestational stages has not been systematically investigated.
In addition, neither has the influence of oxytocin on Magnesium's action been studied throughout gestation. Furthermore, much can be learnt from mouse animal models, but we can find only one study where they have been used to look at Magnesium's relaxant effect, and that was on day 14 of pregnancy in lipopolysaccharide (LPS)-treated animals 27 .
The aim of this study therefore was to investigate whether the relaxant effects of Magnesium are altered by gestational state and to test the hypothesis that the stimulation provided by oxytocin will significantly reduce the relaxant effects of Magnesium. 28 . Basal or control MgSO 4 therefore was 1.2mM. Oxytocin was prepared in distilled water and added to the PSS to give a final concentration of 0.5nM (pregnant tissues) or 1nM (non-pregnant tissues). A 1nM concentration of oxytocin was used for non-pregnant tissues to ensure a similar stimulation to that seen in pregnant tissues was achieved. The concentration of water did not exceed 0.01%. All chemicals were obtained from Sigma UK.
Methods

F
Tissue collection and preparation 19
Non-pregnant, 14-and 16-day (referred to as mid-pregnant) and 18 day (term) pregnant mice were humanely killed using CO 2 anaesthesia and cervical dislocation, in accordance with UK Home Office regulations. All mice used were between 8-10 weeks old. The uterus was removed, cleaned of placentas and membranes (where applicable) and full-thickness (endometrium intact) myometrial strips (1 x 2 x 10 mm) were dissected along the longitudinal axis 21 . Using surgical thread, individual strips were mounted between a fixed support and a 10g isometric force transducer (World Precision Instruments, UK) within a 5ml tissue bath (Linton Instruments, UK) under a resting tension of 5mN and were continuously superfused with oxygenated (95% O2, 5% CO2) PSS at pH 7.4, at a rate of 5mL/min and maintained at 37 o C to mimic physiological conditions 29 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   7 For spontaneous contractions, strips were allowed to equilibrate for 45-60 minutes until regular, frequent and equal amplitude contractions were observed. For oxytocin-induced contractions, strips achieved regular spontaneous activity as above, ahead of addition of oxytocin which remained in the superfusate throughout. The uterine strips were then exposed to increasing concentrations of MgSO 4 from 2 -10 mM (spontaneous) and 2 -12 mM (oxytocin-induced) for 15 minutes or MgSO 4 or MgCl 2 (10mM and 20mM), either in the presence or absence of oxytocin.
Experimental protocol
Analysis and statistics
Myometrial contractions were continuously recorded via the force transducer connected to a data acquisition system equipped with Labtrax software (World Precision Instruments, UK) 29 . For each recording, the amplitude, frequency and force integral (area under the curve, 
Results
Control data and effects of Magnesium on late-pregnant mouse myometrium.
As there were little or no data concerning the actions of Magnesium on mouse myometrium, initial experiments were performed to, determine that Magnesium affected contractility, that the effects of MgSO 4 were due to Magnesium and not the anion, and to obtain an indicative concentration for concentration-response curves.
As shown in Figures 1A and 1B 70 + 14% and 77 + 9%; AUC: 50 + 7 and 58 + 2%, respectively, nor were any significant differences found between MgSO 4 or MgCl 2 during spontaneous activity (data not shown).
Based on these data, the remaining experiments were performed using MgSO 4 as it is the sulfated form which is used clinically, and the effects of different concentrations and gestation were examined.
Effects of Magnesium on spontaneous contractions at different gestational states.
The effects of the application of increasing concentrations of MgSO 4 in the superfusate bathing the spontaneously contracting myometrial strips were examined and compared at day 14, 16 and 18 of pregnancy, and non-pregnant. Concentration-dependent inhibitory Figure 2D ). The increased effects of Magnesium with gestation can also be appreciated from the fact that, in non-pregnant, day 14 and 16 tissues, contractions were abolished in just 1/22 preparations (on day 16), whereas at term, Magnesium abolished contractions in over half the tissues (6/11 preparations). In all preparations however, including those where contractions were abolished (e.g. Figure 2D Table 2 .
Effects of Magnesium on oxytocin-induced contractions at different gestational stages.
Unlike spontaneous activity, in the presence of oxytocin, the myometrium was still producing significant amounts of force at 10mM Magnesium in all preparations. In order therefore to accurately plot concentration-response curves, assist with curve fitting and better understand the response of the tissue, Magnesium was increased to 12 and 20 mM. Typical responses to 20mM Magnesium are shown in Figure 1C .
As is clear in the example traces in Figure 3 , for all pregnant tissues, a less potent inhibition with Magnesium was found in the presence of oxytocin compared to its application to spontaneous contractions, i.e. without oxytocin ( Figure 2 ). Additionally, in pregnant tissues, concentration-response curves for Magnesium in the presence of oxytocin were also shifted to the right compared to spontaneous contractions ( Figure 3E 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Our data showed that, a consequence of oxytocin significantly increasing the IC 50 values in all pregnant tissues, was that there were no longer any gestational differences between them, in the effects of Magnesium (Figure 4) . In other words, there was no significant differences in the inhibitory effect of Magnesium as pregnancy progressed, unlike what had been found above for spontaneous conditions. Instead, in the presence of oxytocin, the potency of MgSO 4 was reduced such that it was similar to its potency in non-pregnant tissues irrespective of pregnancy.
Discussion
Magnesium has been reported to suppress myometrial contractions and for this reason has been used over the last five decades in the treatment of preterm labour. Many clinical studies however, including Cochrane reviews 3 , conclude or suggest that MgSO 4 is ineffective at delaying labour. Thus, the clinical use of MgSO 4 in the treatment of preterm labour is questioned [30] [31] [32] , highlighting the need for further studies. This study was conducted to better understand the effects of Magnesium on uterine contractility. It was designed to examine if physiological changes, namely gestational state and hormonal background, could influence myometrial responses to Magnesium. In this way, a better understanding of the disappointing clinical findings will be obtained and perhaps suggest a more stratified approach to its use as a tocolytic, to help prevent preterm labour. Magnesium's effects as a tocolytic may synergise with its use and action to treat eclampsia. Our data provide fresh insights, as they show that preterm myometrium is much less sensitive to the relaxant effects of Magnesium than term myometrium, which could explain its lack of clinical efficacy. If oxytocin was present, its efficacy was further decreased, at all gestational stages. Thus, taken together we conclude that Magnesium's actions are influenced by both gestational state and hormones, such that, at least in mice, it is least effective in early gestation with oxytocin present, and most effective at term in the absence of oxytocin.
In vitro Mouse myometrium
We conducted our study on mouse myometrium so that we could obtain myometrial preparations at several stages of gestation as well as non-pregnant tissue. Myometrium from pregnant mouse has previously been reported to produce rhythmic spontaneous contractions in vitro for many hours 21 . Consistent with this, we found all the uterine strips generated spontaneous contractions which were stable within a period of 45 -60 minutes, and remained regular without significant reduction in amplitude or frequency for many hours. This therefore allowed the effect of incremental concentrations of Magnesium to be examined and concentration-response curves to be fitted. There has been just one previous report of Magnesium's actions on mouse myometrium, in a lipopolysaccharide model of preterm birth 27 . These authors only studied mid-gestation (14 day) uterus and reported inhibition of spontaneous contractions with Magnesium; an effect which was decreased by lipopolysaccharide. Our findings of an inhibitory effect on term-and non-pregnant myometrium are consistent with findings in other species 10, 12, 14, 15, 33 including humans. Future 
Magnesium's mechanism of action in myometrium.
The effect of MgSO 4 on contractions at different gestational stages was investigated and our data shows that regardless of gestational age or pregnancy status, it can reduce myometrial contractions. This inhibitory effect was reversible and the prompt recovery after washout suggests no ill effects of Magnesium on myometrium, even at high concentrations. The concentrations of MgSO 4 used by us in vitro were empirically determined, and in the case of oxytocin-evoked contractions, going in to pharmacological rather than physiological concentrations, to enable maximal effects to be obtained.
It is unlikely that intracellular Magnesium will have risen during the course of the experimental protocol, due to the activity of Na + -Mg 2+ exchangers and intracellular buffers 34 , as well as Magnesium's slow penetrability through cell membranes 35 . That the effects of Magnesium on the myometrium are relatively rapid and reversible, suggests that its main mechanism of action is likely to be extracellular. The rapid reversal of Magnesium's effect is clinically useful, for example if delivery is by cesarean section, as it reduces the risk of postpartum haemorrhage 36 . Magnesium use in preeclampsia has been associated with increased post-partum haemorrhage in some studies 37 , but in another study, its use was not associated with additional blood loss 38 . The major mechanism of Magnesium's action to relax uterine smooth muscle is, as with other excitable tissues, due to its cationic competition with Calcium 15 . In myometrium, contractions, whether spontaneous or agonist induced, are critically dependent upon Calcium entry through L-type Calcium channels 39, 40 . Thus when increased Magnesium competes with Calcium, entry of Calcium falls and hence contractions reduce and can even be abolished, as we and others have shown 13 . The fall in intracellular Calcium will also lead to a fall in the Calcium content of the sarcoplasmic reticulum (SR) 41 . This reduced SR Calcium available when agonists such as oxytocin produce IP 3 , will reduce their ability, to increase myometrial contractility 15 . In this way, Magnesium will be expected to reduce the force of spontaneous and oxytocin-induced contractions. Fomin et al., (2006) showed that MgSO 4 reduced spontaneous, oxytocin-and KCl-induced myometrial contractility and all were associated with a decrease in intracellular Calcium 34 . In addition, they found no shift in the force-Ca relationship in the myometrium. Together this provides strong evidence that Magnesium's effects are predominantly extracellular and on Calcium entry.
At all gestations and in non-pregnant tissue, our data show a significant reduction in force and frequency of contractions with addition of MgSO 4 . A reduction in force is most likely because of Magnesium's antagonistic effect with Calcium at L-type calcium channels, as discussed above. Frequency of contractions is mainly dependent on excitability and membrane potential, hence a reduction in frequency suggests the pacemaker activity may also be affected by MgSO 4 
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. For example, should differences in the resting membrane potential of some pacemaker cells exist, it may make them more susceptible to the effects of Magnesium leading to fewer action potentials being triggered 42 . Our figures throughout show that, a decrease in the frequency of contractions usually preceded a fall in force. This 44, 45 , hence reducing the likelihood of frequent, synchronous contractions being produced.
Gestational effects
In spontaneous contractions, the effect of MgSO 4 was most potent at term, and least potent in non-pregnant tissues. The latter group were not staged for estrous and should therefore be treated as a mean of any cyclical, estrous changes 46, 47 We found that even on day 16 of gestation, Magnesium's effect on the myometrium was significantly less than at term, suggesting that the changes in sensitivity are on-going throughout pregnancy. Given that the underlying mechanism of Magnesium's effects is via decreasing excitability and Calcium entry, then our findings point to a difference in the Calcium channels with gestation. There have been surprisingly few studies of L-type Calcium expression with gestation in the myometrium.
The work that has been done suggests an increase in expression and changes of subunits from mid-gestation onwards. Tezuka et al (1995) 16 found a marked increase in α1 expression in pregnancy, especially in the last half of gestation until term, followed by a decrease during labour. Similarly, Mershon et al (1994) 17 studied the expression of α 1 subunit and showed a gradual increase in the mRNA towards term followed by a decrease during parturition. They also showed an increase in the number of dihydropyridine binding sites (markers for L-type channels) in the last half of gestation. Thus, a simple effect on Calcium entry is difficult to propose to explain gestational differences, unless the switch to increased α-1 subunits confers an increased susceptibility to Magnesium blockade. Rather, our data suggests that at term the effect of Magnesium is sufficientenough to reduce excitability and make action potential firing less likely, as occurs with its use in neuronal tissues to protect the brain.
Oxytocin and Magnesium
To determine if MgSO 4 can affect contractile parameters in the presence of an agonist, its effect on oxytocin-evoked contractions was determined. Oxytocin was used due to its particular importance to labour. Oxytocin can directly and indirectly stimulate myometrial contractions 19 . Our data show that a greater concentration of Magnesium is needed to inhibit oxytocin-stimulated contractions compared to spontaneous contractions in pregnant tissues. This is in agreement with data from other studies including human myometrium 14, 33 .
However, oxytocin did not significantly change the IC 50 for Magnesium in non-pregnant tissues, from that found for spontaneous contractions. We found this to be the case even when oxytocin was used at 1nM i.e. double the oxytocin concentration used in pregnant tissues. There was no difference in the potency of MgSO 4 on oxytocin-stimulated contractions between the different gestational groups. The greatest shift in Magnesium's potency with oxytocin was observed for term-pregnant myometrium; this shifted the IC 50 from around 3 mM in spontaneous conditions to almost 10 mM. In terms of clinical applications, the effect of oxytocin is to shift the dose from therapeutic to lethal. Therapeutic doses of Magnesium are reported at 2.5 mM (5 mEq/L ) or below 12 , and for seizure management in preeclampsia, 3 mM 33 .
Although oxytocin acts via several mechanisms, an important mechanism is increasing membrane potential (resulting in opening of the L-type Ca 2+ channels and increased Calcium entry), releasing Calcium from the sarcoplasmic reticulum and preventing Calcium exit 19 . These mechanisms will counteract Magnesium's actions and may explain why a greater 19, 48, 49 , an effect attributed to its partitioning into lipid rafts and their effect on signal transduction 50, 51 .
It was also reported that as well as high cholesterol, the high affinity form of the oxytocin receptor requires Magnesium, working as an allosteric modulator. Thus, when Magnesium is increased it may increase the oxytocin signalling and further counter the relaxant effect of Magnesium on Calcium entry.
Transition to labour in humans is associated with increased oxytocin receptor expression 52 , which increases the sensitivity of the uterus towards oxytocin 53 . An increase in oxytocin receptor expression towards term in mouse, has also been shown 53 . Consistent with this is our finding that little, if any, contractility stimulation to 0.5nM oxytocin was observed in nonpregnant tissues and hence the use of 1nM, to assess the effect of oxytocin on the potency of MgSO 4 (control data, not shown). Although not accounting for the lack of gestational differences, the increased drive on contraction produced by oxytocin, and the increased number of receptors, and increased affinity, may also partly explain why a greater concentration of MgSO 4 is needed to inhibit contractions in its presence. In addition, other mechanisms operated by Calcium-independent pathways may also be stimulated by oxytocin and be affected by elevated Magnesium. However, the role of Ca-sensitisation in uterus is thought to be minor 54 . This work, and studies by others, has not considered possible effects of magnesium on potassium channels. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 19 This in vitro study shows that MgSO 4, acting extracellularly , concentration-dependently inhibits spontaneous and oxytocin-induced myometrial contractions in both the pregnant and non-pregnant mouse, with greater efficacy observed in term-pregnant tissues. However, oxytocin decreases the potency of MgSO 4 in pregnant tissues, due to its stimulation of contraction and perhaps due to Magnesium allosterically increasing the affinity of the oxytocin receptor, which may underlie its lack of efficacy as a relaxant i.e. tocolytic, in vivo.
Conclusion
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